-
sodium [(2S,4aR,6R,7R,7aS)-6-(5,6-dichloro-1H-1,3-benzodiazol-1-yl)-7-hydroxy-2-oxo-hexahydro-1,3,5,2λ5-furo[3,2-d][1,3,2λ5]dioxaphosphinin-2-yl]sulfanide
-
ChemBase ID:
153189
-
Molecular Formular:
C12H10Cl2N2NaO5PS
-
Molecular Mass:
419.152731
-
Monoisotopic Mass:
417.9322787
-
SMILES and InChIs
SMILES:
c1c2c(cc(c1Cl)Cl)n(cn2)[C@H]1[C@@H]([C@H]2[C@H](O1)COP(=O)(O2)[S-])O.[Na+]
Canonical SMILES:
O[C@@H]1[C@@H]2OP(=O)([S-])OC[C@H]2O[C@H]1n1cnc2c1cc(Cl)c(c2)Cl.[Na+]
InChI:
InChI=1S/C12H11Cl2N2O5PS.Na/c13-5-1-7-8(2-6(5)14)16(4-15-7)12-10(17)11-9(20-12)3-19-22(18,23)21-11;/h1-2,4,9-12,17H,3H2,(H,18,23);/q;+1/p-1/t9-,10-,11-,12-,22+;/m1./s1
InChIKey:
LXTHVPHQPNCKKG-OIMJWDEGSA-M
-
Cite this record
CBID:153189 http://www.chembase.cn/molecule-153189.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
sodium [(2S,4aR,6R,7R,7aS)-6-(5,6-dichloro-1H-1,3-benzodiazol-1-yl)-7-hydroxy-2-oxo-hexahydro-1,3,5,2λ5-furo[3,2-d][1,3,2λ5]dioxaphosphinin-2-yl]sulfanide
|
|
|
IUPAC Traditional name
|
sodium [(2S,4aR,6R,7R,7aS)-6-(5,6-dichloro-1,3-benzodiazol-1-yl)-7-hydroxy-2-oxo-tetrahydro-4H-1,3,5,2λ5-furo[3,2-d][1,3,2λ5]dioxaphosphinin-2-yl]sulfanide
|
|
|
Synonyms
|
5,6-Dichloro-1-b-D-ribofuranosylbenzimidazole-3′,5′-cyclic monophosphorothioate, Sp- isomer sodium salt
|
Sp 5,6-DCl-cBIMPS
|
|
|
CAS Number
|
|
MDL Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
Acid pKa
|
0.9692167
|
H Acceptors
|
4
|
H Donor
|
1
|
LogD (pH = 5.5)
|
0.7207854
|
LogD (pH = 7.4)
|
0.88058496
|
Log P
|
0.07400952
|
Molar Refractivity
|
85.1375 cm3
|
Polarizability
|
35.845493 Å3
|
Polar Surface Area
|
82.81 Å2
|
Rotatable Bonds
|
1
|
Lipinski's Rule of Five
|
true
|
DETAILS
DETAILS
Sigma Aldrich
Sigma Aldrich -
S6069
|
Biochem/physiol Actions Selective cAMP-dependent protein kinase (PKA) activator. Especially suitable for intact cells showing preference for site B of type II isozyme. Completely stable against mammalian cPDE types I & III and only extremely slowly hydrolized by cPDE type II. Surpasses the widely used but problematic dibutyryl cAMP or 8-CPT-cAMP in terms of metabolic stability, membrane permeability and potency. |
PATENTS
PATENTS
PubChem Patent
Google Patent